nodes	percent_of_prediction	percent_of_DWPC	metapath
Letrozole—CYP2A6—esophageal cancer	0.43	0.512	CbGaD
Letrozole—CYP19A1—esophageal cancer	0.409	0.488	CbGaD
Letrozole—Venous thrombosis—Carboplatin—esophageal cancer	0.00478	0.0453	CcSEcCtD
Letrozole—Edema of lower extremities—Capecitabine—esophageal cancer	0.00278	0.0264	CcSEcCtD
Letrozole—Lymphoedema—Capecitabine—esophageal cancer	0.00228	0.0217	CcSEcCtD
Letrozole—Phlebitis—Carboplatin—esophageal cancer	0.00217	0.0206	CcSEcCtD
Letrozole—CYP19A1—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00213	0.0398	CbGpPWpGaD
Letrozole—Thromboembolic event—Capecitabine—esophageal cancer	0.00207	0.0196	CcSEcCtD
Letrozole—Hemiparesis—Methotrexate—esophageal cancer	0.00198	0.0188	CcSEcCtD
Letrozole—CYP2A6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00193	0.036	CbGpPWpGaD
Letrozole—Coronary artery disease—Cisplatin—esophageal cancer	0.00191	0.0182	CcSEcCtD
Letrozole—CYP2A6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00169	0.0316	CbGpPWpGaD
Letrozole—Bifonazole—CYP19A1—esophageal cancer	0.00157	1	CrCbGaD
Letrozole—Thromboembolic event—Methotrexate—esophageal cancer	0.00154	0.0146	CcSEcCtD
Letrozole—Arterial thrombosis—Methotrexate—esophageal cancer	0.00154	0.0146	CcSEcCtD
Letrozole—Venous thrombosis—Cisplatin—esophageal cancer	0.0014	0.0133	CcSEcCtD
Letrozole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—esophageal cancer	0.0013	0.0243	CbGpPWpGaD
Letrozole—Dysaesthesia—Capecitabine—esophageal cancer	0.00129	0.0122	CcSEcCtD
Letrozole—CYP2A6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00119	0.0223	CbGpPWpGaD
Letrozole—Transient ischaemic attack—Capecitabine—esophageal cancer	0.0011	0.0105	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.00108	0.0202	CbGpPWpGaD
Letrozole—Venous thrombosis—Capecitabine—esophageal cancer	0.00103	0.0098	CcSEcCtD
Letrozole—Night sweats—Capecitabine—esophageal cancer	0.00103	0.0098	CcSEcCtD
Letrozole—Infection—Carboplatin—esophageal cancer	0.000914	0.00867	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.000906	0.0169	CbGpPWpGaD
Letrozole—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.000894	0.0167	CbGpPWpGaD
Letrozole—Nephropathy—Methotrexate—esophageal cancer	0.000871	0.00827	CcSEcCtD
Letrozole—Embolism—Capecitabine—esophageal cancer	0.000868	0.00824	CcSEcCtD
Letrozole—CYP19A1—Endogenous sterols—CYP1B1—esophageal cancer	0.000849	0.0159	CbGpPWpGaD
Letrozole—CYP2A6—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000805	0.015	CbGpPWpGaD
Letrozole—Hypercalcaemia—Capecitabine—esophageal cancer	0.000802	0.00761	CcSEcCtD
Letrozole—Pain—Carboplatin—esophageal cancer	0.000786	0.00746	CcSEcCtD
Letrozole—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.000753	0.00715	CcSEcCtD
Letrozole—Osteoporosis—Methotrexate—esophageal cancer	0.00074	0.00702	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—PHB—esophageal cancer	0.000734	0.0137	CbGpPWpGaD
Letrozole—Rash erythematous—Capecitabine—esophageal cancer	0.000728	0.00691	CcSEcCtD
Letrozole—Pleural effusion—Capecitabine—esophageal cancer	0.000728	0.00691	CcSEcCtD
Letrozole—Body temperature increased—Carboplatin—esophageal cancer	0.000727	0.0069	CcSEcCtD
Letrozole—CYP2A6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000726	0.0136	CbGpPWpGaD
Letrozole—Multiple fractures—Methotrexate—esophageal cancer	0.000714	0.00678	CcSEcCtD
Letrozole—Fracture—Methotrexate—esophageal cancer	0.000714	0.00678	CcSEcCtD
Letrozole—Memory impairment—Capecitabine—esophageal cancer	0.00071	0.00674	CcSEcCtD
Letrozole—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.000707	0.0132	CbGpPWpGaD
Letrozole—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000693	0.00658	CcSEcCtD
Letrozole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000686	0.0128	CbGpPWpGaD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000682	0.0127	CbGpPWpGaD
Letrozole—Polyp—Methotrexate—esophageal cancer	0.000682	0.00647	CcSEcCtD
Letrozole—Vaginal discharge—Methotrexate—esophageal cancer	0.000682	0.00647	CcSEcCtD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000677	0.0127	CbGpPWpGaD
Letrozole—Eye irritation—Capecitabine—esophageal cancer	0.000653	0.00619	CcSEcCtD
Letrozole—Embolism—Methotrexate—esophageal cancer	0.000646	0.00613	CcSEcCtD
Letrozole—CYP19A1—Tryptophan metabolism—ALDH2—esophageal cancer	0.000643	0.012	CbGpPWpGaD
Letrozole—Phlebitis—Cisplatin—esophageal cancer	0.000637	0.00605	CcSEcCtD
Letrozole—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.000622	0.0116	CbGpPWpGaD
Letrozole—Cyst—Methotrexate—esophageal cancer	0.000621	0.00589	CcSEcCtD
Letrozole—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00062	0.0116	CbGpPWpGaD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000598	0.0112	CbGpPWpGaD
Letrozole—Cataract—Capecitabine—esophageal cancer	0.000585	0.00556	CcSEcCtD
Letrozole—Bone pain—Capecitabine—esophageal cancer	0.000582	0.00552	CcSEcCtD
Letrozole—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.000572	0.0107	CbGpPWpGaD
Letrozole—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00056	0.00532	CcSEcCtD
Letrozole—Pulmonary embolism—Capecitabine—esophageal cancer	0.000557	0.00529	CcSEcCtD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000556	0.0104	CbGpPWpGaD
Letrozole—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000549	0.0103	CbGpPWpGaD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000546	0.0102	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000543	0.0101	CbGpPWpGaD
Letrozole—Pleural effusion—Methotrexate—esophageal cancer	0.000542	0.00514	CcSEcCtD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000539	0.0101	CbGpPWpGaD
Letrozole—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.000525	0.0098	CbGpPWpGaD
Letrozole—Irritability—Cisplatin—esophageal cancer	0.000524	0.00497	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000511	0.00955	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—ALDH3A1—esophageal cancer	0.00051	0.00954	CbGpPWpGaD
Letrozole—Neoplasm—Capecitabine—esophageal cancer	0.000504	0.00478	CcSEcCtD
Letrozole—Breast disorder—Cisplatin—esophageal cancer	0.000496	0.00471	CcSEcCtD
Letrozole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000489	0.00915	CbGpPWpGaD
Letrozole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000489	0.00914	CbGpPWpGaD
Letrozole—CYP19A1—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000487	0.00911	CbGpPWpGaD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000482	0.00902	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000476	0.0089	CbGpPWpGaD
Letrozole—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.000475	0.00887	CbGpPWpGaD
Letrozole—Phlebitis—Capecitabine—esophageal cancer	0.00047	0.00446	CcSEcCtD
Letrozole—Thrombophlebitis—Capecitabine—esophageal cancer	0.000467	0.00444	CcSEcCtD
Letrozole—Sweating increased—Cisplatin—esophageal cancer	0.000462	0.00439	CcSEcCtD
Letrozole—Bone disorder—Methotrexate—esophageal cancer	0.000459	0.00436	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—BLVRB—esophageal cancer	0.000455	0.0085	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000443	0.00827	CbGpPWpGaD
Letrozole—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.000437	0.00816	CbGpPWpGaD
Letrozole—Hot flush—Capecitabine—esophageal cancer	0.000432	0.0041	CcSEcCtD
Letrozole—Increased appetite—Capecitabine—esophageal cancer	0.000431	0.00409	CcSEcCtD
Letrozole—Menopausal symptoms—Capecitabine—esophageal cancer	0.000429	0.00407	CcSEcCtD
Letrozole—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000427	0.00798	CbGpPWpGaD
Letrozole—Thirst—Capecitabine—esophageal cancer	0.000425	0.00403	CcSEcCtD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000422	0.00788	CbGpPWpGaD
Letrozole—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000417	0.00396	CcSEcCtD
Letrozole—Arthritis—Capecitabine—esophageal cancer	0.000416	0.00395	CcSEcCtD
Letrozole—Pulmonary embolism—Methotrexate—esophageal cancer	0.000415	0.00394	CcSEcCtD
Letrozole—Myocardial infarction—Cisplatin—esophageal cancer	0.000415	0.00393	CcSEcCtD
Letrozole—Cardiac failure—Capecitabine—esophageal cancer	0.000415	0.00393	CcSEcCtD
Letrozole—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000413	0.00392	CcSEcCtD
Letrozole—Lethargy—Capecitabine—esophageal cancer	0.000413	0.00392	CcSEcCtD
Letrozole—Stomatitis—Cisplatin—esophageal cancer	0.000412	0.00391	CcSEcCtD
Letrozole—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.000411	0.00768	CbGpPWpGaD
Letrozole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—esophageal cancer	0.000407	0.0076	CbGpPWpGaD
Letrozole—Pain in extremity—Capecitabine—esophageal cancer	0.000405	0.00384	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—XRCC3—esophageal cancer	0.000402	0.00752	CbGpPWpGaD
Letrozole—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0004	0.0038	CcSEcCtD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000396	0.00741	CbGpPWpGaD
Letrozole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000394	0.00736	CbGpPWpGaD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000389	0.00727	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—PRDX1—esophageal cancer	0.000387	0.00723	CbGpPWpGaD
Letrozole—Irritability—Capecitabine—esophageal cancer	0.000386	0.00366	CcSEcCtD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000376	0.00702	CbGpPWpGaD
Letrozole—Neoplasm—Methotrexate—esophageal cancer	0.000375	0.00356	CcSEcCtD
Letrozole—Urinary tract disorder—Cisplatin—esophageal cancer	0.000375	0.00356	CcSEcCtD
Letrozole—Connective tissue disorder—Cisplatin—esophageal cancer	0.000373	0.00354	CcSEcCtD
Letrozole—Urethral disorder—Cisplatin—esophageal cancer	0.000372	0.00353	CcSEcCtD
Letrozole—Dry skin—Capecitabine—esophageal cancer	0.000371	0.00352	CcSEcCtD
Letrozole—Breast disorder—Capecitabine—esophageal cancer	0.000366	0.00347	CcSEcCtD
Letrozole—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000364	0.00346	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—ADH7—esophageal cancer	0.000362	0.00677	CbGpPWpGaD
Letrozole—Eye disorder—Cisplatin—esophageal cancer	0.000355	0.00337	CcSEcCtD
Letrozole—Flushing—Cisplatin—esophageal cancer	0.000352	0.00334	CcSEcCtD
Letrozole—Cardiac disorder—Cisplatin—esophageal cancer	0.000352	0.00334	CcSEcCtD
Letrozole—Influenza—Capecitabine—esophageal cancer	0.00035	0.00332	CcSEcCtD
Letrozole—Thrombophlebitis—Methotrexate—esophageal cancer	0.000348	0.0033	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—SLC39A6—esophageal cancer	0.000345	0.00644	CbGpPWpGaD
Letrozole—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.000344	0.00642	CbGpPWpGaD
Letrozole—Mediastinal disorder—Cisplatin—esophageal cancer	0.000342	0.00325	CcSEcCtD
Letrozole—Angina pectoris—Capecitabine—esophageal cancer	0.000341	0.00323	CcSEcCtD
Letrozole—Sweating increased—Capecitabine—esophageal cancer	0.000341	0.00323	CcSEcCtD
Letrozole—Alopecia—Cisplatin—esophageal cancer	0.000335	0.00318	CcSEcCtD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000335	0.00627	CbGpPWpGaD
Letrozole—Malnutrition—Cisplatin—esophageal cancer	0.000331	0.00314	CcSEcCtD
Letrozole—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00033	0.00617	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—ADH7—esophageal cancer	0.000329	0.00615	CbGpPWpGaD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000319	0.00597	CbGpPWpGaD
Letrozole—Weight increased—Capecitabine—esophageal cancer	0.000318	0.00302	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—ADH1B—esophageal cancer	0.000318	0.00594	CbGpPWpGaD
Letrozole—Weight decreased—Capecitabine—esophageal cancer	0.000316	0.003	CcSEcCtD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000315	0.00589	CbGpPWpGaD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000315	0.00589	CbGpPWpGaD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000314	0.00586	CbGpPWpGaD
Letrozole—Infestation—Capecitabine—esophageal cancer	0.000312	0.00296	CcSEcCtD
Letrozole—Infestation NOS—Capecitabine—esophageal cancer	0.000312	0.00296	CcSEcCtD
Letrozole—Vision blurred—Cisplatin—esophageal cancer	0.000311	0.00296	CcSEcCtD
Letrozole—Depression—Capecitabine—esophageal cancer	0.000311	0.00295	CcSEcCtD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00031	0.00578	CbGpPWpGaD
Letrozole—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000307	0.00292	CcSEcCtD
Letrozole—Lethargy—Methotrexate—esophageal cancer	0.000307	0.00292	CcSEcCtD
Letrozole—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000307	0.00292	CcSEcCtD
Letrozole—Ill-defined disorder—Cisplatin—esophageal cancer	0.000307	0.00291	CcSEcCtD
Letrozole—Myocardial infarction—Capecitabine—esophageal cancer	0.000306	0.0029	CcSEcCtD
Letrozole—Stomatitis—Capecitabine—esophageal cancer	0.000304	0.00288	CcSEcCtD
Letrozole—Urinary tract infection—Capecitabine—esophageal cancer	0.000303	0.00288	CcSEcCtD
Letrozole—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.000301	0.00563	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000299	0.00559	CbGpPWpGaD
Letrozole—Malaise—Cisplatin—esophageal cancer	0.000298	0.00283	CcSEcCtD
Letrozole—Leukopenia—Cisplatin—esophageal cancer	0.000296	0.00281	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—CYP26A1—esophageal cancer	0.000295	0.00552	CbGpPWpGaD
Letrozole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000295	0.00551	CbGpPWpGaD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000295	0.00551	CbGpPWpGaD
Letrozole—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000295	0.0028	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000291	0.00545	CbGpPWpGaD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000291	0.00544	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—ADH7—esophageal cancer	0.000288	0.00539	CbGpPWpGaD
Letrozole—Irritability—Methotrexate—esophageal cancer	0.000287	0.00273	CcSEcCtD
Letrozole—Myalgia—Cisplatin—esophageal cancer	0.000281	0.00267	CcSEcCtD
Letrozole—Haemoglobin—Capecitabine—esophageal cancer	0.000281	0.00267	CcSEcCtD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000281	0.00525	CbGpPWpGaD
Letrozole—Anxiety—Cisplatin—esophageal cancer	0.00028	0.00266	CcSEcCtD
Letrozole—Haemorrhage—Capecitabine—esophageal cancer	0.00028	0.00266	CcSEcCtD
Letrozole—Hepatitis—Capecitabine—esophageal cancer	0.00028	0.00266	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000279	0.00265	CcSEcCtD
Letrozole—Hypoaesthesia—Capecitabine—esophageal cancer	0.000278	0.00264	CcSEcCtD
Letrozole—Discomfort—Cisplatin—esophageal cancer	0.000278	0.00264	CcSEcCtD
Letrozole—Urinary tract disorder—Capecitabine—esophageal cancer	0.000276	0.00262	CcSEcCtD
Letrozole—Oedema peripheral—Capecitabine—esophageal cancer	0.000276	0.00262	CcSEcCtD
Letrozole—Connective tissue disorder—Capecitabine—esophageal cancer	0.000275	0.00261	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—GSTO1—esophageal cancer	0.000275	0.00513	CbGpPWpGaD
Letrozole—Urethral disorder—Capecitabine—esophageal cancer	0.000274	0.0026	CcSEcCtD
Letrozole—Breast disorder—Methotrexate—esophageal cancer	0.000272	0.00258	CcSEcCtD
Letrozole—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000271	0.00257	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—GSTO1—esophageal cancer	0.000271	0.00506	CbGpPWpGaD
Letrozole—Anaphylactic shock—Cisplatin—esophageal cancer	0.00027	0.00256	CcSEcCtD
Letrozole—Oedema—Cisplatin—esophageal cancer	0.00027	0.00256	CcSEcCtD
Letrozole—Infection—Cisplatin—esophageal cancer	0.000268	0.00254	CcSEcCtD
Letrozole—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000266	0.00498	CbGpPWpGaD
Letrozole—Erythema multiforme—Capecitabine—esophageal cancer	0.000265	0.00251	CcSEcCtD
Letrozole—Nervous system disorder—Cisplatin—esophageal cancer	0.000265	0.00251	CcSEcCtD
Letrozole—Tachycardia—Cisplatin—esophageal cancer	0.000263	0.0025	CcSEcCtD
Letrozole—Skin disorder—Cisplatin—esophageal cancer	0.000262	0.00249	CcSEcCtD
Letrozole—Eye disorder—Capecitabine—esophageal cancer	0.000262	0.00248	CcSEcCtD
Letrozole—Hyperhidrosis—Cisplatin—esophageal cancer	0.000261	0.00247	CcSEcCtD
Letrozole—Cardiac disorder—Capecitabine—esophageal cancer	0.00026	0.00247	CcSEcCtD
Letrozole—Flushing—Capecitabine—esophageal cancer	0.00026	0.00247	CcSEcCtD
Letrozole—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00026	0.00485	CbGpPWpGaD
Letrozole—Anorexia—Cisplatin—esophageal cancer	0.000257	0.00244	CcSEcCtD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000254	0.00475	CbGpPWpGaD
Letrozole—Angiopathy—Capecitabine—esophageal cancer	0.000254	0.00241	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—ADH1B—esophageal cancer	0.000253	0.00473	CbGpPWpGaD
Letrozole—Mediastinal disorder—Capecitabine—esophageal cancer	0.000252	0.00239	CcSEcCtD
Letrozole—Alopecia—Capecitabine—esophageal cancer	0.000247	0.00235	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000246	0.00233	CcSEcCtD
Letrozole—Mental disorder—Capecitabine—esophageal cancer	0.000245	0.00233	CcSEcCtD
Letrozole—Malnutrition—Capecitabine—esophageal cancer	0.000244	0.00231	CcSEcCtD
Letrozole—Paraesthesia—Cisplatin—esophageal cancer	0.000242	0.0023	CcSEcCtD
Letrozole—Dyspnoea—Cisplatin—esophageal cancer	0.00024	0.00228	CcSEcCtD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000239	0.00447	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—ABCC2—esophageal cancer	0.000239	0.00447	CbGpPWpGaD
Letrozole—Dysgeusia—Capecitabine—esophageal cancer	0.000239	0.00226	CcSEcCtD
Letrozole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000236	0.00441	CbGpPWpGaD
Letrozole—Back pain—Capecitabine—esophageal cancer	0.000236	0.00224	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—CYP26A1—esophageal cancer	0.000235	0.00439	CbGpPWpGaD
Letrozole—Decreased appetite—Cisplatin—esophageal cancer	0.000234	0.00223	CcSEcCtD
Letrozole—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000233	0.00221	CcSEcCtD
Letrozole—Infestation—Methotrexate—esophageal cancer	0.000232	0.0022	CcSEcCtD
Letrozole—Infestation NOS—Methotrexate—esophageal cancer	0.000232	0.0022	CcSEcCtD
Letrozole—Depression—Methotrexate—esophageal cancer	0.000231	0.0022	CcSEcCtD
Letrozole—Pain—Cisplatin—esophageal cancer	0.000231	0.00219	CcSEcCtD
Letrozole—Vision blurred—Capecitabine—esophageal cancer	0.00023	0.00218	CcSEcCtD
Letrozole—Stomatitis—Methotrexate—esophageal cancer	0.000226	0.00215	CcSEcCtD
Letrozole—Ill-defined disorder—Capecitabine—esophageal cancer	0.000226	0.00215	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—ALDH2—esophageal cancer	0.000224	0.00418	CbGpPWpGaD
Letrozole—Sweating—Methotrexate—esophageal cancer	0.000222	0.00211	CcSEcCtD
Letrozole—Feeling abnormal—Cisplatin—esophageal cancer	0.000222	0.00211	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—NFE2L2—esophageal cancer	0.000222	0.00415	CbGpPWpGaD
Letrozole—Malaise—Capecitabine—esophageal cancer	0.00022	0.00209	CcSEcCtD
Letrozole—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000219	0.00208	CcSEcCtD
Letrozole—Vertigo—Capecitabine—esophageal cancer	0.000219	0.00208	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—GSTO1—esophageal cancer	0.000219	0.00409	CbGpPWpGaD
Letrozole—Leukopenia—Capecitabine—esophageal cancer	0.000218	0.00207	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—ANXA1—esophageal cancer	0.000217	0.00406	CbGpPWpGaD
Letrozole—Palpitations—Capecitabine—esophageal cancer	0.000215	0.00204	CcSEcCtD
Letrozole—Body temperature increased—Cisplatin—esophageal cancer	0.000213	0.00202	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—GSTT1—esophageal cancer	0.000213	0.00398	CbGpPWpGaD
Letrozole—Cough—Capecitabine—esophageal cancer	0.000213	0.00202	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—CYP2A6—esophageal cancer	0.000211	0.00393	CbGpPWpGaD
Letrozole—Hypertension—Capecitabine—esophageal cancer	0.00021	0.002	CcSEcCtD
Letrozole—Haemoglobin—Methotrexate—esophageal cancer	0.000209	0.00199	CcSEcCtD
Letrozole—Hepatitis—Methotrexate—esophageal cancer	0.000208	0.00198	CcSEcCtD
Letrozole—Haemorrhage—Methotrexate—esophageal cancer	0.000208	0.00198	CcSEcCtD
Letrozole—Chest pain—Capecitabine—esophageal cancer	0.000207	0.00197	CcSEcCtD
Letrozole—Arthralgia—Capecitabine—esophageal cancer	0.000207	0.00197	CcSEcCtD
Letrozole—Myalgia—Capecitabine—esophageal cancer	0.000207	0.00197	CcSEcCtD
Letrozole—Anxiety—Capecitabine—esophageal cancer	0.000207	0.00196	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000206	0.00196	CcSEcCtD
Letrozole—Urinary tract disorder—Methotrexate—esophageal cancer	0.000206	0.00195	CcSEcCtD
Letrozole—Discomfort—Capecitabine—esophageal cancer	0.000205	0.00195	CcSEcCtD
Letrozole—Urethral disorder—Methotrexate—esophageal cancer	0.000204	0.00194	CcSEcCtD
Letrozole—Dry mouth—Capecitabine—esophageal cancer	0.000203	0.00193	CcSEcCtD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.0002	0.00374	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—PTGS1—esophageal cancer	0.0002	0.00373	CbGpPWpGaD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000199	0.00372	CbGpPWpGaD
Letrozole—Oedema—Capecitabine—esophageal cancer	0.000199	0.00189	CcSEcCtD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000198	0.00369	CbGpPWpGaD
Letrozole—Infection—Capecitabine—esophageal cancer	0.000198	0.00187	CcSEcCtD
Letrozole—Erythema multiforme—Methotrexate—esophageal cancer	0.000197	0.00187	CcSEcCtD
Letrozole—Nervous system disorder—Capecitabine—esophageal cancer	0.000195	0.00185	CcSEcCtD
Letrozole—Eye disorder—Methotrexate—esophageal cancer	0.000195	0.00185	CcSEcCtD
Letrozole—Tachycardia—Capecitabine—esophageal cancer	0.000194	0.00184	CcSEcCtD
Letrozole—Asthenia—Cisplatin—esophageal cancer	0.000194	0.00184	CcSEcCtD
Letrozole—Cardiac disorder—Methotrexate—esophageal cancer	0.000193	0.00184	CcSEcCtD
Letrozole—Skin disorder—Capecitabine—esophageal cancer	0.000193	0.00183	CcSEcCtD
Letrozole—Hyperhidrosis—Capecitabine—esophageal cancer	0.000192	0.00182	CcSEcCtD
Letrozole—Anorexia—Capecitabine—esophageal cancer	0.00019	0.0018	CcSEcCtD
Letrozole—Angiopathy—Methotrexate—esophageal cancer	0.000189	0.00179	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—esophageal cancer	0.000189	0.00353	CbGpPWpGaD
Letrozole—Mediastinal disorder—Methotrexate—esophageal cancer	0.000188	0.00178	CcSEcCtD
Letrozole—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000188	0.00351	CbGpPWpGaD
Letrozole—Diarrhoea—Cisplatin—esophageal cancer	0.000185	0.00175	CcSEcCtD
Letrozole—Alopecia—Methotrexate—esophageal cancer	0.000184	0.00175	CcSEcCtD
Letrozole—Mental disorder—Methotrexate—esophageal cancer	0.000183	0.00173	CcSEcCtD
Letrozole—Malnutrition—Methotrexate—esophageal cancer	0.000181	0.00172	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000181	0.00172	CcSEcCtD
Letrozole—Insomnia—Capecitabine—esophageal cancer	0.00018	0.00171	CcSEcCtD
Letrozole—Paraesthesia—Capecitabine—esophageal cancer	0.000179	0.00169	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—ALDH2—esophageal cancer	0.000178	0.00333	CbGpPWpGaD
Letrozole—Dysgeusia—Methotrexate—esophageal cancer	0.000178	0.00169	CcSEcCtD
Letrozole—Dyspnoea—Capecitabine—esophageal cancer	0.000177	0.00168	CcSEcCtD
Letrozole—Back pain—Methotrexate—esophageal cancer	0.000175	0.00167	CcSEcCtD
Letrozole—Dyspepsia—Capecitabine—esophageal cancer	0.000175	0.00166	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000175	0.00326	CbGpPWpGaD
Letrozole—Decreased appetite—Capecitabine—esophageal cancer	0.000173	0.00164	CcSEcCtD
Letrozole—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000172	0.00163	CcSEcCtD
Letrozole—Vomiting—Cisplatin—esophageal cancer	0.000172	0.00163	CcSEcCtD
Letrozole—Fatigue—Capecitabine—esophageal cancer	0.000171	0.00163	CcSEcCtD
Letrozole—Vision blurred—Methotrexate—esophageal cancer	0.000171	0.00162	CcSEcCtD
Letrozole—Rash—Cisplatin—esophageal cancer	0.00017	0.00161	CcSEcCtD
Letrozole—Constipation—Capecitabine—esophageal cancer	0.00017	0.00161	CcSEcCtD
Letrozole—Pain—Capecitabine—esophageal cancer	0.00017	0.00161	CcSEcCtD
Letrozole—Dermatitis—Cisplatin—esophageal cancer	0.00017	0.00161	CcSEcCtD
Letrozole—CYP19A1—Biological oxidations—CYP1B1—esophageal cancer	0.00017	0.00317	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—GSTT1—esophageal cancer	0.00017	0.00317	CbGpPWpGaD
Letrozole—Ill-defined disorder—Methotrexate—esophageal cancer	0.000168	0.0016	CcSEcCtD
Letrozole—CYP19A1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000167	0.00313	CbGpPWpGaD
Letrozole—Feeling abnormal—Capecitabine—esophageal cancer	0.000164	0.00156	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—esophageal cancer	0.000164	0.00306	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000164	0.00306	CbGpPWpGaD
Letrozole—Malaise—Methotrexate—esophageal cancer	0.000164	0.00155	CcSEcCtD
Letrozole—Vertigo—Methotrexate—esophageal cancer	0.000163	0.00155	CcSEcCtD
Letrozole—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000163	0.00154	CcSEcCtD
Letrozole—Leukopenia—Methotrexate—esophageal cancer	0.000162	0.00154	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000162	0.00303	CbGpPWpGaD
Letrozole—Nausea—Cisplatin—esophageal cancer	0.00016	0.00152	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—ABL1—esophageal cancer	0.00016	0.00299	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—PTGS1—esophageal cancer	0.000159	0.00297	CbGpPWpGaD
Letrozole—Cough—Methotrexate—esophageal cancer	0.000158	0.0015	CcSEcCtD
Letrozole—Urticaria—Capecitabine—esophageal cancer	0.000158	0.0015	CcSEcCtD
Letrozole—Abdominal pain—Capecitabine—esophageal cancer	0.000157	0.00149	CcSEcCtD
Letrozole—Body temperature increased—Capecitabine—esophageal cancer	0.000157	0.00149	CcSEcCtD
Letrozole—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000157	0.00293	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—SMAD4—esophageal cancer	0.000155	0.0029	CbGpPWpGaD
Letrozole—Arthralgia—Methotrexate—esophageal cancer	0.000154	0.00147	CcSEcCtD
Letrozole—Chest pain—Methotrexate—esophageal cancer	0.000154	0.00147	CcSEcCtD
Letrozole—Myalgia—Methotrexate—esophageal cancer	0.000154	0.00147	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000153	0.00146	CcSEcCtD
Letrozole—Discomfort—Methotrexate—esophageal cancer	0.000153	0.00145	CcSEcCtD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000149	0.00279	CbGpPWpGaD
Letrozole—Anaphylactic shock—Methotrexate—esophageal cancer	0.000148	0.0014	CcSEcCtD
Letrozole—Infection—Methotrexate—esophageal cancer	0.000147	0.0014	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—BAX—esophageal cancer	0.000147	0.00274	CbGpPWpGaD
Letrozole—Nervous system disorder—Methotrexate—esophageal cancer	0.000145	0.00138	CcSEcCtD
Letrozole—Skin disorder—Methotrexate—esophageal cancer	0.000144	0.00136	CcSEcCtD
Letrozole—Hyperhidrosis—Methotrexate—esophageal cancer	0.000143	0.00136	CcSEcCtD
Letrozole—Asthenia—Capecitabine—esophageal cancer	0.000143	0.00135	CcSEcCtD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000143	0.00267	CbGpPWpGaD
Letrozole—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000142	0.00266	CbGpPWpGaD
Letrozole—Anorexia—Methotrexate—esophageal cancer	0.000141	0.00134	CcSEcCtD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000141	0.00263	CbGpPWpGaD
Letrozole—Pruritus—Capecitabine—esophageal cancer	0.000141	0.00134	CcSEcCtD
Letrozole—Diarrhoea—Capecitabine—esophageal cancer	0.000136	0.00129	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TP53—esophageal cancer	0.000136	0.00254	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—CYP1B1—esophageal cancer	0.000135	0.00252	CbGpPWpGaD
Letrozole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000135	0.00128	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—TGFBR2—esophageal cancer	0.000134	0.0025	CbGpPWpGaD
Letrozole—Insomnia—Methotrexate—esophageal cancer	0.000134	0.00127	CcSEcCtD
Letrozole—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000134	0.0025	CbGpPWpGaD
Letrozole—Paraesthesia—Methotrexate—esophageal cancer	0.000133	0.00126	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—HMOX1—esophageal cancer	0.000132	0.00247	CbGpPWpGaD
Letrozole—Dyspnoea—Methotrexate—esophageal cancer	0.000132	0.00125	CcSEcCtD
Letrozole—Somnolence—Methotrexate—esophageal cancer	0.000132	0.00125	CcSEcCtD
Letrozole—Dizziness—Capecitabine—esophageal cancer	0.000131	0.00125	CcSEcCtD
Letrozole—Dyspepsia—Methotrexate—esophageal cancer	0.00013	0.00124	CcSEcCtD
Letrozole—Decreased appetite—Methotrexate—esophageal cancer	0.000129	0.00122	CcSEcCtD
Letrozole—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000128	0.00121	CcSEcCtD
Letrozole—Fatigue—Methotrexate—esophageal cancer	0.000128	0.00121	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—CYP19A1—esophageal cancer	0.000127	0.00237	CbGpPWpGaD
Letrozole—Pain—Methotrexate—esophageal cancer	0.000127	0.0012	CcSEcCtD
Letrozole—Vomiting—Capecitabine—esophageal cancer	0.000126	0.0012	CcSEcCtD
Letrozole—Rash—Capecitabine—esophageal cancer	0.000125	0.00119	CcSEcCtD
Letrozole—Dermatitis—Capecitabine—esophageal cancer	0.000125	0.00119	CcSEcCtD
Letrozole—Headache—Capecitabine—esophageal cancer	0.000125	0.00118	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000123	0.0023	CbGpPWpGaD
Letrozole—Feeling abnormal—Methotrexate—esophageal cancer	0.000122	0.00116	CcSEcCtD
Letrozole—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000121	0.00115	CcSEcCtD
Letrozole—Nausea—Capecitabine—esophageal cancer	0.000118	0.00112	CcSEcCtD
Letrozole—Urticaria—Methotrexate—esophageal cancer	0.000118	0.00112	CcSEcCtD
Letrozole—Abdominal pain—Methotrexate—esophageal cancer	0.000117	0.00111	CcSEcCtD
Letrozole—Body temperature increased—Methotrexate—esophageal cancer	0.000117	0.00111	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000116	0.00216	CbGpPWpGaD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000115	0.00215	CbGpPWpGaD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000113	0.00212	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000111	0.00207	CbGpPWpGaD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00011	0.00205	CbGpPWpGaD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000108	0.00202	CbGpPWpGaD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000107	0.00199	CbGpPWpGaD
Letrozole—Asthenia—Methotrexate—esophageal cancer	0.000106	0.00101	CcSEcCtD
Letrozole—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000106	0.00198	CbGpPWpGaD
Letrozole—Pruritus—Methotrexate—esophageal cancer	0.000105	0.000994	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000104	0.00195	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.000103	0.00193	CbGpPWpGaD
Letrozole—Diarrhoea—Methotrexate—esophageal cancer	0.000101	0.000961	CcSEcCtD
Letrozole—Dizziness—Methotrexate—esophageal cancer	9.79e-05	0.000929	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	9.65e-05	0.0018	CbGpPWpGaD
Letrozole—Vomiting—Methotrexate—esophageal cancer	9.41e-05	0.000893	CcSEcCtD
Letrozole—Rash—Methotrexate—esophageal cancer	9.33e-05	0.000886	CcSEcCtD
Letrozole—Dermatitis—Methotrexate—esophageal cancer	9.32e-05	0.000885	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	9.32e-05	0.00174	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	9.27e-05	0.00173	CbGpPWpGaD
Letrozole—Headache—Methotrexate—esophageal cancer	9.27e-05	0.00088	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—BCL2—esophageal cancer	8.93e-05	0.00167	CbGpPWpGaD
Letrozole—Nausea—Methotrexate—esophageal cancer	8.79e-05	0.000834	CcSEcCtD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	8.76e-05	0.00164	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	8.62e-05	0.00161	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—BLVRB—esophageal cancer	8.57e-05	0.0016	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—SLC52A3—esophageal cancer	8.57e-05	0.0016	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	8.5e-05	0.00159	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	8.02e-05	0.0015	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	7.91e-05	0.00148	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	7.67e-05	0.00143	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	7.66e-05	0.00143	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—SLC10A2—esophageal cancer	7.29e-05	0.00136	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CA1—esophageal cancer	7.29e-05	0.00136	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—EP300—esophageal cancer	7.06e-05	0.00132	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—BLVRB—esophageal cancer	6.82e-05	0.00128	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—SLC52A3—esophageal cancer	6.82e-05	0.00128	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CA2—esophageal cancer	6.67e-05	0.00125	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	6.53e-05	0.00122	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.52e-05	0.00122	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	6.21e-05	0.00116	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PLCE1—esophageal cancer	6.2e-05	0.00116	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ADH7—esophageal cancer	6.2e-05	0.00116	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—MYC—esophageal cancer	6.15e-05	0.00115	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	6.14e-05	0.00115	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	6.02e-05	0.00112	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	5.82e-05	0.00109	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—SLC10A2—esophageal cancer	5.8e-05	0.00108	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CA1—esophageal cancer	5.8e-05	0.00108	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ADH1B—esophageal cancer	5.43e-05	0.00102	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CA2—esophageal cancer	5.31e-05	0.000992	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—TYMP—esophageal cancer	5.19e-05	0.000971	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CYP26A1—esophageal cancer	5.05e-05	0.000944	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—TP53—esophageal cancer	5.05e-05	0.000944	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	4.95e-05	0.000925	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ADH7—esophageal cancer	4.93e-05	0.000922	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PLCE1—esophageal cancer	4.93e-05	0.000922	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ALOX15—esophageal cancer	4.92e-05	0.00092	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	4.88e-05	0.000913	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GSTO1—esophageal cancer	4.7e-05	0.000878	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—TPI1—esophageal cancer	4.7e-05	0.000878	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	4.66e-05	0.00087	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	4.59e-05	0.000858	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ALDOB—esophageal cancer	4.5e-05	0.000842	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GAPDH—esophageal cancer	4.33e-05	0.00081	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ADH1B—esophageal cancer	4.33e-05	0.000808	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CRABP1—esophageal cancer	4.3e-05	0.000803	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—TYMP—esophageal cancer	4.13e-05	0.000773	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GNG7—esophageal cancer	4.09e-05	0.000764	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP26A1—esophageal cancer	4.02e-05	0.000752	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ALOX15—esophageal cancer	3.92e-05	0.000732	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ALDH2—esophageal cancer	3.83e-05	0.000716	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GSTO1—esophageal cancer	3.74e-05	0.000699	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—TPI1—esophageal cancer	3.74e-05	0.000699	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GSTT1—esophageal cancer	3.64e-05	0.000681	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CYP2A6—esophageal cancer	3.6e-05	0.000673	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.59e-05	0.00067	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ALDOB—esophageal cancer	3.58e-05	0.00067	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GAPDH—esophageal cancer	3.45e-05	0.000645	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CRABP1—esophageal cancer	3.42e-05	0.000639	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PTGS1—esophageal cancer	3.41e-05	0.000638	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ENO1—esophageal cancer	3.41e-05	0.000638	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PSME2—esophageal cancer	3.36e-05	0.000628	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PSME1—esophageal cancer	3.36e-05	0.000628	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GNG7—esophageal cancer	3.25e-05	0.000608	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ALDH2—esophageal cancer	3.05e-05	0.00057	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.94e-05	0.000549	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CYP1B1—esophageal cancer	2.9e-05	0.000542	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GSTT1—esophageal cancer	2.9e-05	0.000542	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PTGS1—esophageal cancer	2.72e-05	0.000508	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ENO1—esophageal cancer	2.72e-05	0.000508	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PSME1—esophageal cancer	2.68e-05	0.0005	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PSME2—esophageal cancer	2.68e-05	0.0005	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—SLC52A3—esophageal cancer	2.5e-05	0.000468	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—BLVRB—esophageal cancer	2.5e-05	0.000468	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—HMOX1—esophageal cancer	2.49e-05	0.000465	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.44e-05	0.000456	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ABCB1—esophageal cancer	2.39e-05	0.000447	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP1B1—esophageal cancer	2.31e-05	0.000432	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP19A1—esophageal cancer	2.17e-05	0.000406	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CA1—esophageal cancer	2.13e-05	0.000398	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.13e-05	0.000398	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.98e-05	0.00037	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CA2—esophageal cancer	1.95e-05	0.000364	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ABCB1—esophageal cancer	1.9e-05	0.000355	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.81e-05	0.000338	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ADH7—esophageal cancer	1.81e-05	0.000338	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.81e-05	0.000338	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CREBBP—esophageal cancer	1.6e-05	0.000298	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.59e-05	0.000296	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—TYMP—esophageal cancer	1.52e-05	0.000283	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.47e-05	0.000276	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.44e-05	0.000269	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—NOS3—esophageal cancer	1.43e-05	0.000267	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—TPI1—esophageal cancer	1.37e-05	0.000256	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.37e-05	0.000256	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.31e-05	0.000246	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PTGS2—esophageal cancer	1.31e-05	0.000244	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CREBBP—esophageal cancer	1.27e-05	0.000238	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.27e-05	0.000236	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.25e-05	0.000234	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GNG7—esophageal cancer	1.19e-05	0.000223	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NOS3—esophageal cancer	1.14e-05	0.000213	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.12e-05	0.000209	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—EP300—esophageal cancer	1.09e-05	0.000203	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.06e-05	0.000199	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.05e-05	0.000196	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PTGS2—esophageal cancer	1.04e-05	0.000195	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.96e-06	0.000186	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ENO1—esophageal cancer	9.96e-06	0.000186	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PSME1—esophageal cancer	9.81e-06	0.000183	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PSME2—esophageal cancer	9.81e-06	0.000183	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—EP300—esophageal cancer	8.66e-06	0.000162	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP1B1—esophageal cancer	8.47e-06	0.000158	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PIK3CA—esophageal cancer	8.05e-06	0.00015	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.96e-06	0.000149	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—HMOX1—esophageal cancer	7.27e-06	0.000136	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.97e-06	0.00013	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PIK3CA—esophageal cancer	6.4e-06	0.00012	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.66e-06	8.71e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NOS3—esophageal cancer	4.17e-06	7.8e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.82e-06	7.13e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—EP300—esophageal cancer	3.17e-06	5.93e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.35e-06	4.39e-05	CbGpPWpGaD
